MedPath

Validation of an Integrated Digital Solution (SUNrise®) Versus Polysomnography for Obstructive Sleep Apnea Diagnosis

Not Applicable
Completed
Conditions
Obstructive Sleep Apnea
Interventions
Device: Sunrise
Device: polysomnography
Registration Number
NCT05057975
Lead Sponsor
Sunrise
Brief Summary

Validation of an integrated digital solution (SUNrise®) of mandibular movement automatic analysis by artificial intelligence versus polysomnography for obstructive sleep apnea diagnosis: a prospective, randomized, parallel-arm, open-label, multicenter, national, controlled study.

Detailed Description

The new Sunrise integrated digital solution is a disposable 3 gram sensor that sits on the chin for sleep disorders diagnosis. This device records mandibular movements, head movements and position during sleep. Data acquisition is done through a mobile application installed on the user smartphone. Data is then transferred automatically at the end of the test (overnight) to a cloud platform where it is automatically analyzed. The Health Care Professional (HCP) and the patient have access to sleep parameters and report.

The objective of this trial is to determine the place of the Sunrise device in the care pathway in France for patients suspected of having OSA. The assumption is that Sunrise is both non-inferior to the normal practice (i.e., the PSG) on sleepiness at 3 months post-diagnosis, and superior to the PSG (outpatient or in-lab) in terms of time between inclusion and diagnosis appointment and treatment initiation. By speeding up the treatment initiation, the hypothesis is that Sunrise is also superior to the PSG on sleepiness as well as quality of life and work productivity at 3 months post-inclusion. Another assumption is that Sunrise is non-inferior to the PSG on CPAP compliance at 3 months following treatment initiation.

The SUNSAS study will be launched in 19 centers (public and private) in France and will include 848 patients aged 18 to 80 years. Eligible patients will be included and randomized in 2 arms, i.e., the Sunrise arm and the PSG arm. An appointment to discuss the diagnosis and treatment options (for patients suffering from OSA) will be arranged after the procedure (PSG or Sunrise) is performed. On site follow-up visits will be then organized at 3 months post-inclusion and at 3 months post-diagnosis, and a phone call will be scheduled at 3 months post-treatment.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
848
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
SunriseSunriseHome Sleep Test, OSA diagnosis based on mandibular movements recording
PSGpolysomnographyPolysomnography, OSA diagnosis based on local scoring by center
Primary Outcome Measures
NameTimeMethod
Time to treatmentUp to 15 months

To determine the superiority of Sunrise vs PSG in terms of time between inclusion and treatment initiation

Change in daily sleepiness3 months post inclusion

To determine the superiority of Sunrise vs PSG on sleepiness at 3 months post-inclusion using ESS

Time to diagnosisUp to 12 months

To determine the superiority of Sunrise vs PSG in terms of time between inclusion and diagnosis appointment

Secondary Outcome Measures
NameTimeMethod
Comparison of Sunrise versus PSG diagnosisUp to 12 months

To confirm the diagnosis performance of Sunrise compared to PSG by comparing the obstructive respiratory disturbance index (ORDI) in both groups

Change in quality of life3 months post inclusion visit

To determine the superiority of Sunrise vs PSG on quality of life at 3 months post-inclusion using Quebec Sleep Questionnaire (QSQ).

QSQ utilizes 32 items to measure 5 domains: daytime sleepiness, diurnal symptoms, nocturnal symptoms, emotions, and social interactions.Item scores range from 1 to 7. Mean scores for each domain are calculated, and a total score is derived by calculating the mean of all items. Higher scores are associated with better better quality of life.

cost (€)/QALY3 months post-diagnosis

cost (€)/QALY gained 3 months post-diagnosis

Change in work productivity3 months post-inclusion

To determine the superiority of Sunrise vs PSG on work productivity at 3 months post-inclusion using WPAI:SHP

Net profit for the French social securityestimated at 3 years

Estimation of the net profit for the French social security at 3 years

Comparison of CPAP compliance data3 month after treatment initiation

To determine the non-inferiority of Sunrise vs PSG on CPAP compliance measured at 3 months post-treatment by comparing CPAP average usage in both groups

Difference in the obstructive respiratory disturbance index (ORDI)Up to 12 months

To measure the variability of the ORDI by comparing the 3 obstructive respiratory disturbance index (ORDI) measures provided by the Sunrise device (used 3 nights)

Trial Locations

Locations (19)

CHU de Reims - Hôpital Maison Blanche

🇫🇷

Reims, France

Hôpitaux Universitaires de Paris Seine Saint-Denis (HUPSSD, AP-HP),

🇫🇷

Bobigny,, France

CHU Angers

🇫🇷

Angers, France

Nouvelle clinique Bel-Air

🇫🇷

Bordeaux, France

CHU Bordeaux - Hôpital Pellegrin

🇫🇷

Bordeaux, France

Chu Grenoble Alpes,

🇫🇷

Grenoble, France

AP-HP Hôpital Henri Mondor

🇫🇷

Créteil, France

CHRU Lille - Hôpital Roger Salengro

🇫🇷

Lille, France

Hôpital Européen Marseille

🇫🇷

Marseille, France

CHU Lyon - Hôpital de la Croix-Rousse

🇫🇷

Lyon, France

Hôpital privé la Louvière

🇫🇷

Lille, France

CHU Montpellier - Hôpital Gui-de-Chauliac

🇫🇷

Montpellier, France

CHRU de Nancy - Hôpital d'Adultes de Brabois

🇫🇷

Nancy, France

AP-HP Pitié Salpêtrière

🇫🇷

Paris, France

AP-HP Hôpital Bichat-Claude Bernard

🇫🇷

Paris, France

Polyclinique Saint-Laurent

🇫🇷

Rennes, France

AP-HP CUP Hôpital Hôtel Dieu

🇫🇷

Paris, France

Centre du Sommeil de Grenoble

🇫🇷

Saint-Martin-d'Hères, France

CHU de Toulouse - Hôpital Larrey

🇫🇷

Toulouse, France

© Copyright 2025. All Rights Reserved by MedPath